Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Data Help Size Up Novel Class Of SGLT-2 Inhibitors In Diabetes

Executive Summary

Though probable class side effects of urinary tract and genital infections remain worrisome, SGLT-2 inhibitors nevertheless have potential as add-ons to multiple kinds of diabetes drugs, based on data released at the recent American Diabetes Association meeting
Advertisement

Related Content

Bristol Outperforms In Q3, But Will Dapagliflozin, Apixaban See It Past Plavix?
FDA's Dapagliflozin Review To Focus On Hepatic Effects, Cancer Risks
Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug
Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug
Dapagliflozin Performance In Phase III Leaves Concerns,Particularly About Urinary Infections
Dapagliflozin Performance In Phase III Leaves Concerns,Particularly About Urinary Infections
Dapagliflozin Performance In Phase III Leaves Concerns, Particularly About Urinary Infections
Big Pharma Tries Out New Class On The Diabetes Block: SGLT-2
Both AstraZeneca/Bristol Diabetes Drugs Should Meet FDA Guidance

Topics

Advertisement
UsernamePublicRestriction

Register

PS052398

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel